A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

MIT researchers discovered that the genome’s 3D structure doesn’t vanish during cell division as previously thought. Instead, ...

Please provide your email address to receive an email when new articles are posted on . A CRISPR-Cas9-based therapy reduced transthyretin levels in patients with hereditary amyloidosis and ...